首页
>
>
投稿咨询
微信添加科研助理

了解相关问题

加急服务
微信添加科研助理

了解相关问题

CANCER LETTERS
ISSN：0304-3835

CANCER LETTERS

CANCER LETT
学科领域：医学
是否预警：不在预警名单内
是否OA：否
录用周期：约2.7个月
新锐分区：医学1区
年发文量：560
影响因子：10.1
JCR分区：Q1

基本信息

《癌症快报》是一本在癌症研究的广泛领域提供全文文章快速出版的杂志。该杂志的重点是癌症的分子和细胞生物学、癌基因、癌发生、放射生物学、分子病理学、激素和癌症、病毒肿瘤学、癌症和转移生物学、分子细胞遗传学、流行病学;和实验治疗学。发表主要标准是多学科读者感兴趣。论文应该在技术上是合理的，并有足够的实验细节作为依据。如果临床论文有助于理解疾病的基本机制，则可以接受。
0304-3835SCIE/Scopus收录
10.1
点击查看最新影响趋势>
11
新
2026年3月发布
点击查看历史分区趋势    >
大类学科小类学科Top期刊综述期刊
医学1区
ONCOLOGY 肿瘤学
1区
是
N/A
新
WOS期刊SCI分区  2024-2025最新升级版
按JIF指标学科分区收集子录JIF分区JIF排名百分位
学科：ONCOLOGY
SCIE
Q1
30/328
按JCR指标学科分区收集子录JCR分区JCR排名百分位
学科：ONCOLOGY
SCIE
Q1
25/328
161
560
点击查看年发文量趋势图>
40%约52.27%约2.7个月-医学-肿瘤学
16.8%
点击查看自引率趋势图>
时间预警情况
2026年03月发布的新锐学术版不在预警名单中
2025年03月发布的2025版不在预警名单中
2024年02月发布的2024版不在预警名单中
2023年01月发布的2023版不在预警名单中
2021年12月发布的2021版不在预警名单中
2020年12月发布的2020版不在预警名单中
90.89%24.55%5.6%
CiteScore：13.90
SJR：2.756
SNIP：1.544
学科类别分区排名百分位
大类：Medicine
小类：Oncology
Q1
38 / 415
大类：Medicine
小类：Cancer Research
Q1
31 / 233

期刊高被引文献

Selonsertib (GS-4997), an ASK1 inhibitor, antagonizes multidrug resistance in ABCB1- and ABCG2-overexpressing cancer cells.
来源期刊：Cancer lettersDOI：10.1016/j.canlet.2018.10.007
A novel, liver-specific long noncoding RNA LINC01093 suppresses HCC progression by interaction with IGF2BP1 to facilitate decay of GLI1 mRNA.
来源期刊：Cancer lettersDOI：10.1016/j.canlet.2019.02.033
Treg-mediated acquired resistance to immune checkpoint inhibitors.
来源期刊：Cancer lettersDOI：10.1016/j.canlet.2019.05.003
tRNA-derived fragments and tRNA halves: The new players in cancers.
来源期刊：Cancer lettersDOI：10.1016/j.canlet.2019.03.012
CAR-NK for tumor immunotherapy: Clinical transformation and future prospects.
来源期刊：Cancer lettersDOI：10.1016/j.canlet.2019.11.033
Aptamer-functionalized liposomes for targeted cancer therapy.
来源期刊：Cancer lettersDOI：10.1016/j.canlet.2019.01.045
Long non-coding RNA HULC activates HBV by modulating HBx/STAT3/miR-539/APOBEC3B signaling in HBV-related hepatocellular carcinoma.
来源期刊：Cancer lettersDOI：10.1016/j.canlet.2019.04.008
New inhibitor of the TAp73 interaction with MDM2 and mutant p53 with promising antitumor activity against neuroblastoma.
来源期刊：Cancer lettersDOI：10.1016/j.canlet.2019.01.014
Glycochenodeoxycholate promotes hepatocellular carcinoma invasion and migration by AMPK/mTOR dependent autophagy activation.
来源期刊：Cancer lettersDOI：10.1016/j.canlet.2019.04.009
Towards the first targeted therapy for triple-negative breast cancer: Repositioning of clofazimine as a chemotherapy-compatible selective Wnt pathway inhibitor.
来源期刊：Cancer lettersDOI：10.1016/j.canlet.2019.02.018
Reversible regulation of SATB1 ubiquitination by USP47 and SMURF2 mediates colon cancer cell proliferation and tumor progression.
来源期刊：Cancer lettersDOI：10.1016/j.canlet.2019.01.039
Androgen deprivation-induced ZBTB46-PTGS1 signaling promotes neuroendocrine differentiation of prostate cancer.
来源期刊：Cancer lettersDOI：10.1016/j.canlet.2018.10.004
Single-cell transcriptome analysis reveals tumor immune microenvironment heterogenicity and granulocytes enrichment in colorectal cancer liver metastases.
来源期刊：Cancer lettersDOI：10.1016/j.canlet.2019.10.016
Emerging strategies in cancer therapy combining chemotherapy with immunotherapy.
来源期刊：Cancer lettersDOI：10.1016/j.canlet.2019.04.017
Regorafenib antagonizes BCRP-mediated multidrug resistance in colon cancer.
来源期刊：Cancer lettersDOI：10.1016/j.canlet.2018.10.032
Liquid biopsy in Ovarian cancer using Circulating Tumor DNA and Cells: Ready for Prime Time?
来源期刊：Cancer lettersDOI：10.1016/j.canlet.2019.10.014
Human UTP14a promotes colorectal cancer progression by forming a positive regulation loop with c-Myc.
来源期刊：Cancer lettersDOI：10.1016/j.canlet.2018.10.010
Notch Signaling in Breast Cancer: From Pathway Analysis to Therapy.
来源期刊：Cancer lettersDOI：10.1016/j.canlet.2019.07.012
Inhibition of GSK-3β activity suppresses HCC malignant phenotype by inhibiting glycolysis via activating AMPK/mTOR signaling.
来源期刊：Cancer lettersDOI：10.1016/j.canlet.2019.08.003
Multiple myeloma cell-derived IL-32γ increases the immunosuppressive function of macrophages by promoting indoleamine 2,3-dioxygenase (IDO) expression.
来源期刊：Cancer lettersDOI：10.1016/j.canlet.2019.01.012
Preclinical comparison of regorafenib and sorafenib efficacy for hepatocellular carcinoma using multimodality molecular imaging.
来源期刊：Cancer lettersDOI：10.1016/j.canlet.2019.03.037
TRPM4 channel and cancer.
来源期刊：Cancer lettersDOI：10.1016/j.canlet.2019.04.012
Melatonin inhibits MLL-rearranged leukemia via RBFOX3/hTERT and NF-κB/COX-2 signaling pathways.
来源期刊：Cancer lettersDOI：10.1016/j.canlet.2018.11.037
miR-193a-3p inhibition of the Slug activator PAK4 suppresses non-small cell lung cancer aggressiveness via the p53/Slug/L1CAM pathway.
来源期刊：Cancer lettersDOI：10.1016/j.canlet.2019.01.027
Carbohydrate-based adjuvants activate tumor-specific Th1 and CD8+ T-cell responses and reduce the immunosuppressive activity of MDSCs.
来源期刊：Cancer lettersDOI：10.1016/j.canlet.2018.10.013
H22954, a novel long non-coding RNA down-regulated in AML, inhibits cancer growth in a BCL-2-dependent mechanism.
来源期刊：Cancer lettersDOI：10.1016/j.canlet.2019.03.055
Oncogene addiction as a foundation of targeted cancer therapy: The paradigm of the MET receptor tyrosine kinase.
来源期刊：Cancer lettersDOI：10.1016/j.canlet.2018.12.001
Sex Disparities in Cancer.
来源期刊：Cancer lettersDOI：10.1016/j.canlet.2019.08.017
Synergistic activity of BET inhibitor MK-8628 and PLK inhibitor Volasertib in preclinical models of medulloblastoma.
来源期刊：Cancer lettersDOI：10.1016/j.canlet.2018.12.012
Chromosome fragility in the buccal epithelium in patients with Fanconi anemia.
来源期刊：Cancer lettersDOI：10.1016/j.canlet.2019.12.008
Clinical Lipidomics In Understanding Of Lung Cancer: Opportunity And Challenge.
来源期刊：Cancer lettersDOI：10.1016/j.canlet.2019.08.014
Combined Bcl-2/Src inhibition synergize to deplete stem-like breast cancer cells.
来源期刊：Cancer lettersDOI：10.1016/j.canlet.2019.05.004
MicroRNA-182-5p regulates hedgehog signaling pathway and chemosensitivity of cisplatin-resistant lung adenocarcinoma cells via targeting GLI2.
来源期刊：Cancer lettersDOI：10.1016/j.canlet.2019.10.044
Anterior Gradient-2 monoclonal antibody inhibits lung cancer growth and metastasis by upregulating p53 pathway and without exerting any toxicological effects: A preclinical study.
来源期刊：Cancer lettersDOI：10.1016/j.canlet.2019.01.025
Tumor vasculature remodeling by radiation therapy increases doxorubicin distribution and efficacy.
来源期刊：Cancer lettersDOI：10.1016/j.canlet.2019.05.005
DMBX1 promotes tumor proliferation and regulates cell cycle progression via repressing OTX2-mediated transcription of p21 in lung adenocarcinoma cell.
来源期刊：Cancer lettersDOI：10.1016/j.canlet.2019.03.045
BIRC5 is a target for molecular imaging and detection of human pancreatic cancer.
来源期刊：Cancer lettersDOI：10.1016/j.canlet.2019.04.036
Vps4A mediates the localization and exosome release of β-catenin to inhibit epithelial-mesenchymal transition in hepatocellular carcinoma.
来源期刊：Cancer lettersDOI：10.1016/j.canlet.2019.04.035
Interference with the Bromodomain Epigenome Readers Drives p21 Expression and Tumor Senescence.
来源期刊：Cancer lettersDOI：10.1016/j.canlet.2019.06.019
Endothelin-converting enzyme-1 in cancer aggressiveness.
来源期刊：Cancer lettersDOI：10.1016/j.canlet.2019.03.033
NFX1-123 is highly expressed in cervical cancer and increases growth and telomerase activity in HPV 16E6 expressing cells.
来源期刊：Cancer lettersDOI：10.1016/j.canlet.2019.02.024
PI3Kα inhibitors sensitize esophageal squamous cell carcinoma to radiation by abrogating survival signals in tumor cells and tumor microenvironment.
来源期刊：Cancer lettersDOI：10.1016/j.canlet.2019.05.040
Mycoplasma infection promotes tumor progression via interaction of the mycoplasmal protein p37 and epithelial cell adhesion molecule in hepatocellular carcinoma.
来源期刊：Cancer lettersDOI：10.1016/j.canlet.2019.04.007
Nerve growth factor (NGF)-TrkA axis in head and neck squamous cell carcinoma triggers EMT and confers resistance to the EGFR inhibitor erlotinib.
来源期刊：Cancer lettersDOI：10.1016/j.canlet.2019.12.015
The covalent CDK7 inhibitor THZ1 enhances temsirolimus-induced cytotoxicity via autophagy suppression in human renal cell carcinoma.
来源期刊：Cancer lettersDOI：10.1016/j.canlet.2019.12.005
HS-173 as a novel inducer of RIP3-dependent necroptosis in lung cancer.
来源期刊：Cancer lettersDOI：10.1016/j.canlet.2018.12.006
Mutant p53R175H promotes cancer initiation in the pancreas by stabilizing HSP70.
来源期刊：Cancer lettersDOI：10.1016/j.canlet.2019.03.047
Technical differences between sequencing and microarray platforms impact transcriptomic subtyping of colorectal cancer.
来源期刊：Cancer lettersDOI：10.1016/j.canlet.2019.10.040
Aromatase-induced endogenous estrogen promotes tumour metastasis through estrogen receptor-α/matrix metalloproteinase 12 axis activation in castration-resistant prostate cancer.
来源期刊：Cancer lettersDOI：10.1016/j.canlet.2019.09.001
A pharmacogenomic analysis using L1000CDS2 identifies BX-795 as a potential anticancer drug for primary pancreatic ductal adenocarcinoma cells.
来源期刊：Cancer lettersDOI：10.1016/j.canlet.2019.08.002

相关文章

Materials Today Bio解析：IF=8.7，8天初审
2025-11-25
《ZEITSCHRIFT FUR GEBURTSHILFE UND NEONATOLOGIE》德国老牌产科期刊免版面费、非预警，毕业保底首选！
2025-11-25
Journal of Multidisciplinary Healthcare：IF= 2.4，中科院3区，JCR Q2，多学科综合医学开放获取期刊，应用性强，审稿迅速，编辑反馈专业！
2025-10-15
European Journal of Medical Genetics：IF= 1.7，中科院4区，JCR Q3，医学遗传学期刊，涵盖分子遗传学、临床基因诊断与罕见病研究，欧洲地区影响力较稳，国际传播适中！
2025-10-15
ANNALS OF ONCOLOGY：中科院1区，肿瘤学，接受率为25%
2025-10-15
Journal of Cystic Fibrosis：权威官方背景，高影响力，整体周期约 3 个月，部分 1 天录用
2025-10-15
JOURNAL OF INHERITED METABOLIC DISEASE：影响因子平稳，学术认可度高，年发文稳定，4个月录用
2025-10-15
JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL HYGIENE：自引风险小，审稿周期短，发表难度低，但if持续下降
2025-10-15
Neurobiology of Stress：中科院 2 区，认可度高，国人发文第二，机会公平
2025-10-15
NATURE REVIEWS DRUG DISCOVERY：中科院1区，生物工程与应用微生物，药学，接受率为21%
2025-10-15

期刊推荐

Acta Biomaterialia封面

Acta Biomaterialia

学科领域：医学
影响因子：9.6
中科院分区： 1区
ACTA PHARMACOLOGICA SINICA封面

ACTA PHARMACOLOGICA SINICA

学科领域：医学
影响因子：8.4
中科院分区： 1区
ADVANCED DRUG DELIVERY REVIEWS封面

ADVANCED DRUG DELIVERY REVIEWS

学科领域：医学
影响因子：17.6
中科院分区： 1区
AGEING RESEARCH REVIEWS封面

AGEING RESEARCH REVIEWS

学科领域：医学
影响因子：12.4
中科院分区： 1区
论文发表 2-4个月录用 7500+文章录用 不成功可退款
新
2026年3月发布（新锐分区）
大类学科小类学科Top期刊综述期刊
医学1区
ONCOLOGY 肿瘤学
1区
是
N/A
2025年3月升级版
大类学科小类学科Top期刊综述期刊
医学1区
ONCOLOGY 肿瘤学
2区
是
否
2023年12月旧的升级版
大类学科小类学科Top期刊综述期刊
医学1区
ONCOLOGY 肿瘤学
2区
是
否